In this episode, Greg and Rob are joined by healthcare attorney Jeff Davis, to discuss how the Medicare drug pricing provisions in the IRA will impact 340B providers.  They’ll go over CMS billing modifier requirements (15:27), share opinions on the financial impact covered entities might experience (38:02), and how various legal challenges to the IRA by the pharma industry may play out (56:29).  They also add some insights around CMS’s proposed Part B payment remedy (1:01:03).

In the intro, Rob catches Greg up on new manufacturer restrictions, and some recent HRSA audit experience related to interpreting data request list (DRL) revisions, and shares some commentary on the current House E&C subcommittee hearing on proposed drug shortage legislation.

Email us questions, thoughts, and ideas for podcast topics at [email protected]!

Rob and Greg continue their conversation with health care attorney and 340B expert Emily Cook (21:05).  They discuss thoughts on the CMS Medicare Part B remedy, provide some commentary on the Inflation Reduction Act (IRA) and its intersection with 340B covered entities, and address an issue that could impact hospital DSH eligibility in the future.

In the intro, Greg and Rob are joined by SpendMend colleague Jennifer Hagen and catch up on recent 340B developments, including updates on manufacturer restrictions, follow-up from a prior question about CAR-T therapy, as well as Spendmend’s reference within an amicus brief filed in the Genesis case. Finally, the team recaps recent changes discovered in the HRSA audit data request list (DRL).

If you have any questions or topic suggestions, please email [email protected].

Rob and Greg are joined by Emily Cook (20:15), an attorney in the health care and 340B space. They discuss a number of 340B topics, including ongoing manufacturer restrictions of contract pharmacies (24:52) as well as legal challenges to HRSA’s patient definition (42:16). This is part one of a two-part series, so look for a future podcast episode with more conversation among Rob, Greg, and Emily.

In the intro, the guys catch up on some news and noteworthy 340B items, including drug shortage legislation, state-level 340B developments, tips on addressing manufacturer repayment notifications, and reminders about hospital-CE recertification. 

Aiden shares the 340B questions sent in by our listeners, and there are some good ones. Questions include opening an in-house retail pharmacy, CAR-T therapy, continuum of care and 190 clinics, the IRA, and a couple of other fun ones.

On our one-year anniversary, we want to thank everyone for listening and for all the encouragement we have received.

Rob and Greg continue to unpack all the great information gathered from the 2023 340B Coalition Summer Conference in Washington D.C.  They chat with coworkers, clients, and friends in the 340B community to share insights from sessions at the Conference.  Guests include SpendMend colleagues Jennifer Hagen (16:54) and Shakita Carter (38:12), as well as 340B hospital experts Erin Leigh (47:12), Nan Kempadoo (1:00:14) and Pooja Shah (1:14:08). 

Submit your questions for Rob and Greg here: https://ww2.spendmend.com/340b-unscripted-qa/

Greg and Rob share highlights from the 340B Coalition Conference in DC. Topics covered include proposed CMS repayment for affected hospitals, Inflation Reduction Act updates, legislative updates, and other worthy conference discussions. 

Greg and Rob break down the ins and outs of the Medicare Cost Report and the dos and don'ts of child site registrations. They also provide an update on contract pharmacy manufacturer restrictions and information on the upcoming 340B Coalition Conference. We also hear from our Producer Aiden and provide the secret password for your free 340B Unscripted t-shirt at the conference. 

In this episode, Greg and Rob talk about an important 340B Program compliance element – preventing Medicaid duplicate discounts.  They discuss the importance of maintaining the Medicaid Exclusion File (MEF), challenges with managing state-specific billing requirements, and strategies for managing out-of-state Medicaid.

In the intro, the guys review updates to manufacturer restrictions for contract pharmacies and share anecdotes from recent HRSA audit experiences. 

In this episode, Greg and Rob discuss a recent publication regarding how 340B Program participation may impact the degree of biosimilar utilization.  Additionally, the guys recap recent legislative proposals with 340B impact that were advanced by the House Energy & Commerce Committee.  

Article citation:  Health Affairs 42, NO. 5 (2023): 632–641 

In this episode, Rob and Greg discuss an interesting piece of 340B history – the Morford letter (25:31).  Rob shares his understanding of the origins of the letter and contemporary application of the letter as it relates to the recent debate around the 340B-eligible patient definition.

But first, the guys catch up on 340B news, including: 

To access a copy of the Morford Letter: http://content.spendmend.com/assets/Morford-Letter-1.26.01.pdf